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Abstract: The synthesis of two protected tetrasaccharide pentenyl glycosides with diarabinan and
digalactan branching related to the pectic polysaccharide rhamnogalacturonan I is reported. The
strategy relies on the coupling of N-phenyl trifluoroacetimidate disaccharide donors to a common
rhamnosyl acceptor. The resulting trisaccharide thioglycosides were finally coupled to an n-pentenyl
galactoside acceptor to access the two protected branched tetrasaccharides.
Keywords: pectin; rhamnogalacturonan I; branched RG-I; oligosaccharide synthesis
1. Introduction
Pectins are the most structurally complex polysaccharides found in plant cell walls. These
highly heterogeneous polysaccharides are fundamental components of the primary cell wall of plants
where they modulate plant cell functions such as support, defense, signaling, and cell adhesion [1,2].
They also play a vital role in the food industry, serving as stabilizing and thickening agents in
products such as jams, yogurt, and jellies [3]. Furthermore, it has been documented that they are
useful in the production of biodegradable films, materials for biomedical implantation, and in drug
delivery [4–6]. Rhamnogalacturonan I (RG-I) is one of the structural classes of pectic polysaccharides,
along with homogalacturonan, rhamnogalacturonan II, xylogalacturonan, and apiogalacturonan [7].
The chemical structure of RG-I consists of a backbone with alternating units of α-linked L-rhamnose
and D-galacturonic acid. The backbone has numerous branches at the C-4 position of the L-rhamnose
residues including galactans, arabinans, or arabinogalactans. Galactans are mostly linear chains of
β-(1→4)-linked D-galactose residues. Arabinans are chains of α-(1→5)-linked L-arabinofuranosides
that are frequently branched at C-3 and sometimes at C-2. The most frequent form of arabinogalactan
side chains is arabinogalactan I, which is a β-(1→4)-galactan with arabinan branches [8,9]. To the
best of our knowledge, except for the synthesis of tri- and tetrasaccharide building blocks containing
a single galactose unit as a side chain by Vogel and co-workers [10,11], branched RG-I fragments
have not previously been addressed by chemical synthesis [12]. These structures are of great interest
because they are useful for the study of pectin and the enzymes involved in both the biosynthesis and
degradation of RG-I [1,2,7,13,14]. Herein, we report the synthesis of two protected tetrasaccharides
with diarabinan and digalactan branching, designed for the assembly of larger RG-I oligosaccharides.
The retrosynthetic analysis of targets 1 and 2 is depicted in Scheme 1. We invisioned that both
targets could be obtained in a linear synthetic strategy with the last glycosylation involving the
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same galactosyl acceptor 3. We have previously succesfully used galactosides in the assembly of an
unprotected hexasaccharide backbone fragment of RG-I using a post-glycosylation-oxidation strategy,
which has also been successfully applied by others [15–17]. The two trisaccharides 4 and 5 could be
assembled by employing the common acceptor 6 forming the disaccharidic backbone unit for both
targets. The putative side chain consisting of digalactan 7 can be assembled by glycosylating galactose
acceptor 9 with donor 10. Likewise, diarabinan 8 can be derived from 11.
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2. Results and Discussion
Starting from β-D-galactose pentaacetate, galactosyl acceptor 3 was synthesized according to our
previous work [18,19] and the diol 12 was accessed as reported earlier [20]. After masking the free
hydroxyl groups of compound 12 as benzoyl esters a regioselective opening [21–23] of the benzylidene
acetal resulted in acceptor 9 in 70% yield over two steps (Scheme 2).
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Scheme 2. Synthesis of t - t l galactoside 9.
The N-phenyl trifluoroacetimidate donor 10 was prepared from commercially available
D-galactose in four steps [24]. Rhamnosyl acceptor 6 was obtained in two steps from L-rhamnose
(Scheme 3). Triol 13 [25] was transformed into the diol 14 [26] by a tin-mediated regioselective
benzylation of the C-3 hydroxyl group. The higher acidity of the C-2 alcohol was exploited to protect it
as a NAP-ether. In the literature [27], there is an example of a selective benzylation of a C-2 hydroxyl
group in a similar rhamnose derivative under phase-transfer conditions, however, we observed low
yields using the same reaction conditions du to the formation of the regioisom r. Th NAP-protected
rhamnoside 6 was instead synthesized by r acting th diol 14 with NAPBr in the presence of sodium
hydride and TBAI resulting in 6 in 65% yield (Scheme 3).
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Scheme 3. Synthesis of the rhamnosyl acceptor 6.
The synthesis f the digalactan N-phenyl trifluoroacetimidate donor 7 started by
TMSOTf-promoted glycosylation of acceptor 9 with the perbenzoylated donor 10. The reactants
were mixed at −40 ◦C and then immediately warmed to 0 ◦C. The reaction mixture was left stirring at
this temperature for 3 h resulting in disaccharide 15 in 76% yield. The hydrolysis of the n-pentenyl
group was achieved in two steps: first 15 was titrated with bromine at 0 ◦C, and then the resulting
bromide was treated directly with silver(I) carbonate in a mixture of acetone and water. This approach
afforded the corresponding hemiacetal, which was further reacted with N-phenyl trifluoroacetimidoyl
chloride in the presence of cesium carbonate to give the digalactan donor 7 in 60% yield over three
steps (Scheme 4).
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Rhamnose acceptor 6 was then glycosylated with donor 7 followed by a Zemplén deacylation
yielding the trisaccharide 16 in 77% yield over two steps. Global benzylation gave trisaccharide donor
4 in 79% yield (Scheme 5).Molecules 2018, 23, x 4 of 14 
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Having prepared the trisaccharide thiophenyl donor 4, we investigated the coupling with
galactose acceptor 3. We examined different promoters: NIS/TESOTf, NIS/Yb(OTf)3, MeOTf,
Ph2SO/Tf2O, DMTST, Me2S2/Tf2O, but in all cases, the yield of the desired product was unsatisfactory.
Furthermore, screening of these reaction conditions with monomeric building blocks mainly generated
a C-glycoside through an intramolecular cyclization of the NAP moiety, as also observed by
Crich et al. [28]. Clearly, the NAP-group had to be replaced to avoid the formation of the cyclized
by-product, and the chloroacetyl (ClAc) ester was chosen as it can be removed selectively in the
presence of the C-6 ace yl group.
Treatment of 4 with DDQ in th presence of water in a mixture of CH2Cl2 and m hanol afforded
the corresponding alcohol. The free hydroxyl group was then protected as a chloroacetyl ster by
treating it with chloroacetic anhydride under basic conditions (59% over two steps). A mixture of
donor 17 and galactose acceptor 3 in CH2Cl2 was treated with Ph2SO/Tf2O and giving the target
tetrasaccharide 1 in 42% yield (Scheme 6).
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Scheme 6. Synthesis of tetrasaccharide 1.
Next, we turned our attention to the synthesis of tetrasaccharide 2. Diarabinan N-phenyl
trifluoroacetimidate donor 8 was prepared in six steps starting from the arabinose donor 11 [29]
similar to previous work by Varrot and coworkers [30] (Scheme 7).
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Scheme 7. Synthesis of the diarabinan N-phenyl trifluoroacetimidate donor 8.
We also explored an alternative route to the disaccharide 18 (Scheme 7). Triol 19 [30] was
transformed into the fully protected arabinose derivative through a two-step, one-pot protocol.
Subsequently, the TBDPS-group was removed by treatment with TBAF (62% over two steps). The
resulting alcohol 20 was coupled with donor 11 to give 18 in 92% yield. The benzyl group was
used as temporary prot ction of the anomeric positi n in 18. Catalytic hydr genolysis pr ided
the corres onding hemiacetal, which was transformed into the target disaccharide donor 8 in 80%
over two steps. The synthesis of the diarabinan-c ntaining tris ccharide 5 is shown in Scheme 8.
TMSOTf-mediated coupli g of 8 with rhamnose accept r 6 afforded trisaccharide 21 in 84% yield. The
presence of the participating benzoyl group at the C-2 position of donor 8 ensured the formation of the
α-glycosidic linkage. The benzoyl esters of 21 were exchanged with benzyl protective groups in two
steps (68% yield) giving trisaccharide donor 5.
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Scheme 8. Synthesis of the diarabinan-containing trisaccharide donor 5.
For the synthesis of the diarabinan-containing trisaccharide donor 5, an alternative approach to
the one described above also gave excellent results, as shown in Scheme 9. The rhamnose acceptor
6 was glycosylated with arabinose donor 11 followed by deacylation under Zemplén conditions
providing triol 22 (70% yield over two steps). Selective glycosylation of the primary alcohol using
donor 11 afforded the partially protected trisaccharide 23 in 68% yield. Protecting group manipulations
gave 5 in 75% yield over two steps. This approach allowed us to reach trisaccharide 5 in five steps
from 6 and 11.
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Scheme 9. Synthesis of trisaccharide 5 by an alternative approach.
As discussed previously, the NAP-group was exchanged with a chloroacetyl ester to give 24 in
69% yield over two steps. Final glycosylation of galactosyl acceptor 3 with trisaccharide donor 24 was
performed, using Ph2SO/Tf2O as a promoter at −60 ◦C, resulting in the desired tetrasaccharide 2 in
42% yield (Scheme 10).
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3. Materials and Methods
3.1. General Information
Starting materials, eagents, and solvent were purchased from commercial supp iers and have
been used without further purification. All solvents were HPLC-grade. Anhydrous solvents were
obtained from Innovative Technology PS-MD-7 Pure-solv solvent purification system (Innovative
Technology, Pewaukee, WI, USA). The reactions were carried out in flame-dried glassware under an
inert atmosphere unless stated otherwise. Thin-layer chromatography (TLC) was performed on Merck
(Merck, Darmstadt, Germany) Aluminium Sheets pre-coated with silica, C-60 F254 plates. Compounds
were visualized by charring after dipping in CAM stain (Ce(SO4)2 (1.6 g) and (NH4)6Mo7O24 (4 g) in
10% sulphuric acid (200 mL). Eluent systems re specified f r ach Rf value, and ratios are given as
volume ratios. Evaporation of solvents was p rformed with a VWR Internation l Laborota 400 under
reduced pressure (i vacuo) at t mperatures ranging betwee 35–55 ◦C. Trace solvent was removed
under reduced pressure using a vacuum pump (Edwards, Burgess Hill, UK). Flash chro atography
was performed using Matrex 60 Å silica gel (35–70 µm, Merck, Darmstadt, Germany) as the stationary
phase by the general procedure developed by Still et al. [31]. The eluent system is specified by the
protocol for each synthesis. Eluent ratios are given as volume ratios. NMR-spectra were recorded on
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a Varian Mercury 300 B (Varian, Palo Alto, CA, USA), Bruker Ascend 400, Bruker Avance 800 MHz,
Bruker DQX 400 or Bruker AC 500 spectrometer (Bruker, Billerica, MA, USA). Chemical shifts (δ)
are reported in ppm and coupling constants in Hz. Solvents used for NMR experiments were
CDCl3, CD3OD, D2O or d6-DMSO and their resonances were used as internal standards. Most
of the compounds have been characterized by NMR.
3.2. General Procedures
General Procedure I for Glycosylation with N-Phenyl Trifluoroacetimidate Glycosyl Donors
A mixture of the donor (1.2 equiv.) and the acceptor (1.0 equiv.) was co-evaporated with toluene
and subjected to high vacuum for 2 h. The mixture was dissolved in anhydrous CH2Cl2 (c. 0.1–0.01 M)
and cooled to −40 ◦C. TMSOTf (0.1 equiv.) was added, and the reaction mixture was stirred at −40 ◦C
until TLC showed completion of the reaction (10–30 min). The reaction mixture was quenched by
addition of Et3N, evaporated and purified by flash column chromatography.
General Procedure II for Preparation of the N-Phenyl Trifluoroacetimidate Glycosyl Donors
Hemiacetal (1.0 equiv.) was dissolved in CH2Cl2 (c. 0.1–0.01 M). PhNC(Cl)CF3 (2.0 equiv.)
and Cs2CO3 (2.0 equiv.) were added and the reaction mixture was stirred at 20 ◦C until TLC
showed completion of the reaction (2–5 h). The reaction mixture was filtered through a plug of
Celite, concentrated, and the residue was purified by flash column chromatography.
General Procedure III for Removal of Acyl Protective Groups (Zemplén Conditions)
The starting material was dissolved in MeOH (c. 0.1–0.01 M) or, in a 1:1 mixture of MeOH
and THF. A freshly prepared 1 M NaOMe solution (0.1 equiv.) in MeOH was added. The reaction
mixture was stirred at 20 ◦C until TLC showed the full conversion (1–24 h). The reaction mixture was
then quenched by addition of Amberlite IR-120 (H+). The resin was filtered off, and the filtrate was
concentrated, and purified by flash column chromatography.
General Procedure IV for Benzylation of Hydroxyl Groups
To a solution of the starting material (1.0 equiv.) in DMF, BnBr (1.2 equiv. for 1-OH) and TBAI
(0.01 equiv.) were added, and the mixture was cooled in an ice bath. NaH (1.2 equiv. for 1-OH) was
added and the mixture was stirred at 20 ◦C for 15 h and then quenched by addition of MeOH. The
reaction mixture was partially concentrated, diluted with EtOAc and washed with water and brine.
The organic phase was dried over Na2SO4, concentrated and purified by flash column chromatography.
General Procedure V for Removal of the 2-Naphthylmethyl (NAP) Group
The protected saccharide (1.0 equiv.) was dissolved in a 4:1 mixture of CH2Cl2 and MeOH.
Water (2%) was added followed by addition of DDQ (1.4 equiv.). The reaction mixture was stirred
at 20 ◦C until TLC showed completion of the reaction (2–5 h). The reaction mixture was diluted
with CH2Cl2 and washed with sat. NaHCO3. The combined aqueous phases were extracted with
CH2Cl2. The combined organic phases were dried over Na2SO4, filtered, concentrated and purified by
flash chromatography.
General Procedure VI for Introducing a Chloroacetyl (ClAc) Group
Alcohol (1.0 equiv.) was dissolved in anhydrous CH2Cl2 and cooled in an ice bath. Et3N (2.0 equiv.)
was added followed by addition of ClAc2O (1.1 equiv.). The reaction mixture was stirred at 0 ◦C for
2 h, then warmed up to 20 ◦C, diluted with CH2Cl2 and washed with 0.1 M HCl. The organic phase
was dried over Na2SO4, concentrated and purified by flash column chromatography.
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General Procedure VII the Ph2SO/Tf2O-Promoted Glycosylation
A mixture of the donor (1.2 equiv.), Ph2SO (1.2 equiv.) and TTBP (1.2 equiv.) was co-evaporated
with toluene and subjected to high vacuum for 2 h. The mixture was dissolved in anhydrous CH2Cl2
and cooled to −60 ◦C. Tf2O (1.3 equiv.) was added, and the reaction mixture was stirred at −60 ◦C
for 5 min. Afterwards, a solution of the acceptor (1.0 equiv.) in anhydrous CH2Cl2 was added. The
mixture was warmed to −40 ◦C over 2 h and Et3N was added. The mixture was diluted with CH2Cl2
and washed with brine, dried over Na2SO4, concentrated and purified by flash chromatography.
Pent-4-enyl 2,3-di-O-benzoyl-6-O-benzyl-β-D-galactopyranoside 9
Compound 12 (4 g, 11.90 mmol) was dissolved in CH2Cl2 (100 mL) followed by the addition of
Et3N (5.0 mL, 35.70 mmol), DMAP (9 mg, 0.39 mmol) and benzoyl chloride (3.5 mL, 29.75 mmol). The
reaction mixture was stirred until TLC revealed full conversion (3 h). The reaction was quenched with
MeOH (10 mL), washed with water (2 × 100 mL), dried over MgSO4 and concentrated. The product
was purified by flash chromatography (toluene/EtOAc 19:1) to afford the corresponding product as
a white powder. Yield 6.0 g (94%). Rf 0.44 (9:1 toluene/EtOAc). 1H-NMR (400 MHz, CDCl3) δ 7.91
(m, 4H), 7.54–7.36 (m, 4H), 7.35–7.24 (m, 7H), 5.79 (dd, J = 10.4, 8.0 Hz, 1H), 5.58 (ddt, J = 16.2, 10.9,
6.7 Hz, 1H), 5.47 (s, 1H), 5.29 (dd, J = 10.4, 3.6 Hz, 1H), 4.76–4.69 (m, 2H), 4.66 (d, J = 8.0 Hz, 1H), 4.51
(dd, J = 3.6, 1.0 Hz, 1H), 4.32 (dd, J = 12.4, 1.6 Hz, 1H), 4.06 (dd, J = 12.4, 1.8 Hz, 1H), 3.89 (dt, J = 9.6,
6.1 Hz, 1H), 3.59 (m, 1H), 3.46 (ddd, J = 9.6, 7.3, 6.2 Hz, 1H), 1.99–1.79 (m, 2H), 1.68–1.42 (m, 2H).
13C-NMR (101 MHz, CDCl3) δ 166.3, 165.3, 138.0, 137.6, 133.4, 133.1, 130.0, 129.8, 129.8, 129.2, 129.0,
128.5, 128.4, 128.2, 126.4, 114.8, 101.3, 101.0, 73.7, 72.9, 69.2, 69.1, 68.9, 66.6, 29.9, 28.6.
Trifluoroacetic acid (7.0 mL, 91.88 mmol) was added dropwise to a solution of the above mentioned
compound (10.0 g, 18.37 mmol) and triethylsilane (14.7 mL, 91.88 mmol) in CH2Cl2 (75 mL) at 0 ◦C.
When the addition was complete (10 min), the reaction was heated to 22 ◦C and stirred for 5 h. The
mixture was diluted with EtOAc and washed with sat. aq. NaHCO3 and brine, dried over MgSO4,
filtered and concentrated. The product was purified by flash chromatography (19:1 toluene/EtOAc) to
afford 9 as a white amorphous solid. Yield: 7.1 (72%). Rf 0.38 (9:1 toluene/EtOAc). 1H-NMR (400 MHz,
CDCl3) δ 7.95–7.85 (m, 4H), 7.47–7.38 (m, 2H), 7.33–7.19 (m, 9H), 5.75–5.65 (dd, J = 9.5 Hz, 1H), 5.57
(ddt, J = 15.7, 11.2, 6.6 Hz, 1H), 5.21 (dt, J = 9.5, 1.6 Hz, 1H), 4.76–4.73 (m, 2H), 4.60 (d, J = 9.5 Hz,
1H), 4.52 (m, 2H), 4.31–4.28 (m, 1H), 3.85 (dt, J = 9.7, 6.2 Hz, 1H), 3.80–3.69 (m, 3H), 3.51–3.39 (m, 1H),
1.98–1.81 (m, 2H), 1.62–1.45 (m, 2H).13C-NMR (101 MHz, CDCl3) δ 165.9, 165.3, 137.9, 137.6, 137.6,
133.3, 133.0, 129.8, 129.6, 129.1, 128.5, 128.4, 128.3, 127.8, 127.8, 114.7, 101.5, 74.4, 74.4, 73.8, 73.3, 69.7,
69.2, 69.1, 68.1, 29.8, 28.6.
Phenyl 3-O-benzyl-2-O-(2-naphthylmethyl)-1-thio-α-L-rhamnopyranoside 6
To a solution of diol 14 (700 mg, 2.0 mmol) in DMF (6 mL) NAPBr (490 mg, 2.2 mmol) and TBAI
(75 mg, 0.2 mmol) were added and the mixture was cooled in an ice bath. NaH (90 mg, 2.2 mmol,
60% in oil) was added and the mixture was stirred at 20 ◦C for 12 h and then quenched by addition of
MeOH. The reaction mixture was partially concentrated, diluted with EtOAc and washed with water
and brine. The combined water phase was extracted with EtOAc. The combined organic phase was
dried over Na2SO4, concentrated and purified by flash chromatography (19:1 toluene/EtOAc) to afford
6 as a colorless oil. Yield 640 mg (65%). Rf 0.22 (toluene/EtOAc 20:1). 1H-NMR (300 MHz, CDCl3) δ
7.75–7.66 (m, 4H), 7.41–7.38 (m, 3H), 7.60–7.16 (m, 10H), 5.49 (d, J = 1.2 Hz, 1H), 4.80 (d, J = 12.4 Hz,
1H), 4.64 (d, J = 12.4 Hz, 1H), 4.49 (d, J = 11.7 Hz, 1H), 4.37 (d, J = 11.7 Hz, 1H), 4.06–4.01 (m, 1H),
4.00–3.98 (m, 1H), 3.76 (t, J = 9.4 Hz, 1H), 3.58 (dd, J = 9.5, 3.0 Hz, 1H), 2.26 (s, 1H), 1.30 (d, J = 6.1 Hz,
3H); 13C-NMR (75 MHz, CDCl3) δ 137.5, 135.0, 134.4, 133.0, 132.9, 131.1, 128.9, 128.4, 128.1, 127.8, 127.8,
127.5, 127.2, 126.7, 126.0, 125.8, 85.7, 79.5, 75.4, 71.9, 71.7, 71.4, 69.6, 17.6.
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Pent-4-enyl 2,3,4,6-tetra-O-benzoyl-β-D-galactopyranosyl-(1→4)-2,3-di-O-benzoyl-6-O-benzyl-
β-D-galactopyranoside 15
Prepared from 9 and 10 according to the General Procedure I. White amorphous solid, 76%. Rf 0.35
(toluene/EtOAc 10:1). 1H-NMR (300 MHz, CDCl3) δ 8.00–7.93 (m, 4H), 7.91–7.69 (m, 8H), 7.49–7.12 (m,
23H), 5.80–5.76 (m, 2H), 5.58–5.45 (m, 2H), 5.43–5.28 (m, 2H), 4.98 (d, J = 7.9 Hz, 1H), 4.74 (d, J = 1.1 Hz,
1H), 4.69 (m, 2H), 4.58 (d, J = 7.5 Hz, 1H), 4.54 (d, J = 5.6 Hz, 1H), 4.47 (d, J = 2.8 Hz, 1H), 4.32 (dd,
J = 11.2, 6.5 Hz, 1H), 4.22 (dd, J = 11.3, 6.6 Hz, 1H), 3.94 (t, J = 6.5 Hz, 1H), 3.88–3.74 (m, 4H), 3.47–3.34
(m, 1H), 1.89–1.78 (m, 2H), 1.56–1.40 (m, 2H); 13C-NMR (75 MHz, CDCl3) δ 166.7, 166.6, 166.4, 166.2,
165.3, 138.8, 138.8, 134.4, 134.1, 133.6, 130.8, 130.7, 130.6, 130.5, 130.5, 130.5, 130.4, 130.3, 130.0, 129.8,
129.5, 129.4, 129.2, 129.1, 129.0, 129.0, 128.5, 128.5, 115.4, 102.0, 101.7, 74.9, 74.6, 74.5, 74.0, 72.6, 72.0,
70.9, 70.4, 70.3, 69.3, 68.9, 62.5, 30.6, 29.3.
2,3,4,6-Tetra-O-benzoyl-β-D-galactopyranosyl-(1→4)-2,3-di-O-benzoyl-6-O-benzyl-
D-galactopyranosyl N-phenyl trifluoroacetimidate 7
The hemiacetal was prepared from pentenyl glycoside 15 as described for a similar compound in
the literature [32] and it was converted into 7 according to the General Procedure II. White foam, 85%.
The product was verified by NMR spectroscopy as an α/β mixture and was used in the subsequent
glycosylation without further characterization.
Phenyl β-D-galactopyranosyl-(1→4)-6-O-benzyl-β-D-galactopyranosyl-(1→4)-3-O-benzyl-2-O-
(2-naphthylmethyl)-1-thio-α-L-rhamnopyranoside 16
Compound 16 was prepared from 6 and 7 according to the General Procedure I and subjected to
conditions from General Procedure III without further purification. White amorphous solid, 77%. Rf
0.25 (CH2Cl2/MeOH 10:1). 1H-NMR (300 MHz, CDCl3) δ 7.73–7.52 (m, 5H), 7.42–7.01 (m, 17H), 5.34
(s, 1H), 4.66–4.24 (m, 8H), 4.05–3.25 (m, 16H), 1.24 (d, J = 5.0 Hz, 3H); 13C-NMR (75 MHz, CDCl3) δ
138.0, 137.6, 135.0, 134.3, 133.0, 132.9, 131.1, 128.9, 128.5, 128.4, 128.3, 128.2, 127.8, 127.6, 127.4, 127.2,
126.8, 126.0, 125.9, 125.8, 105.7, 104.1, 85.5, 79.5, 79.2, 75.9, 74.5, 73.9, 73.6, 73.0, 72.6, 72.4, 72.2, 72.0, 68.9,
68.6, 68.3, 61.0, 17.8.
Phenyl 2,3,4,6-tetra-O-benzyl-β-D-galactopyranosyl-(1→4)-2,3,6-tri-O-benzyl-β-D-galactopyranosyl-
(1→4)-3-O-benzyl-2-O-(2-naphthylmethyl)-1-thio-α-L-rhamnopyranoside 4
Prepared from 16 according to the General Procedure IV. White amorphous solid, 78%. Rf 0.27
(toluene/EtOAc 20:1). 1H-NMR (400 MHz, CDCl3) δ 7.73–7.55 (m, 4H), 7.42–7.31 (m, 6H), 7.29–7.05
(m, 45H), 5.37 (d, J = 1.7 Hz, 1H), 5.02 (d, J = 11.0 Hz, 1H), 4.96 (d, J = 7.6 Hz, 1H), 4.89 (d, J = 11.6 Hz,
1H), 4.82 (d, J = 7.7 Hz, 1H), 4.76–4.59 (m, 6H), 4.54 (d, J = 11.5 Hz, 1H), 4.49 (d, J = 11.6 Hz, 1H), 4.46
(s, 1H), 4.34–4.25 (m, 4H), 4.16 (d, J = 11.2 Hz, 1H), 4.10–3.99 (m, 1H), 3.93 (t, J = 9.1 Hz, 1H), 3.83–3.76
(m, 2H), 3.74–3.63 (m, 4H), 3.57–3.50 (m, 2H), 3.50–3.44 (m, 2H), 3.43–3.32 (m, 5H), 1.27 (d, J = 6.1 Hz,
1H); 13C-NMR (101 MHz, CDCl3) δ 139.2, 139.0, 138.9, 138.8, 138.5, 138.5, 138.2, 137.9, 135.2, 134.5,
133.1, 132.9, 131.4, 128.9, 128.3, 128.3, 128.2, 128.2, 128.2, 128.1, 128.1, 128.0, 128.0, 127.9, 127.7, 127.7,
127.7, 127.6, 127.5, 127.5, 127.4, 127.3, 127.3, 127.2, 127.2, 127.1, 126.8, 126.0, 126.0, 125.8, 102.8, 102.2,
85.8, 82.4, 81.8, 80.4, 80.2, 79.7, 76.5, 76.1, 75.3, 74.6, 74.6, 74.3, 73.4, 73.4, 73.3, 73.1, 73.1, 72.3, 72.3, 72.0,
69.3, 69.1, 69.0, 68.6, 17.9.
Phenyl 2,3,4,6-tetra-O-benzyl-β-D-galactopyranosyl-(1→4)-2,3,6-tri-O-benzyl-β-D-galactopyranosyl-
(1→4)-3-O-benzyl-1-thio-α-L-rhamnopyranoside S1
Prepared from 4 according to the General Procedure V. White amorphous solid, 73%. Rf 0.23
(toluene/EtOAc 10:1). 1H-NMR (400 MHz, CDCl3) δ 7.39–7.31 (m, 4H), 7.27–7.07 (m, 39H), 7.04
(d, J = 7.8 Hz, 2H), 5.39 (d, J = 1.3 Hz, 1H), 4.99 (d, J = 11.0 Hz, 1H), 4.92 (d, J = 7.6 Hz, 1H), 4.87
(d, J = 11.6 Hz, 1H), 4.74–4.66 (m, 3H), 4.65–4.52 (m, 5H), 4.46 (d, J = 11.6 Hz, 1H), 4.41 (s, 2H), 4.31
(d, J = 10.8 Hz, 1H), 4.28–4.18 (m, 4H), 4.12–4.02 (m, 1H), 4.01–3.98 (m, 1H), 3.77–3.71 (m, 2H), 3.71–3.61
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(m, 4H), 3.53–3.41 (m, 2H), 3.40–3.29 (m, 4H), 2.24 (s, 1H), 1.20 (d, J = 6.2 Hz, 3H); 13C-NMR (101 MHz,
CDCl3) δ 139.0, 138.9, 138.7, 138.5, 138.4, 137.8, 137.6, 131.3, 128.9, 128.3, 128.3, 128.2, 128.2, 128.1, 128.1,
128.1, 128.1, 128.0, 127.8, 127.8, 127.7, 127.7, 127.7, 127.4, 127.3, 127.3, 127.3, 127.2, 125.2, 102.9, 102.2,
86.8, 82.3, 81.8, 80.5, 80.3, 79.7, 76.1, 75.4, 74.6, 74.6, 74.2, 73.4, 73.4, 73.3, 73.1, 72.3, 72.1, 69.7, 69.4, 69.1,
68.7, 68.3, 17.7. Copies of NMR spectra in Supplementary Materials.
Phenyl 2,3,4,6-tetra-O-benzyl-β-D-galactopyranosyl-(1→4)-2,3,6-tri-O-benzyl-β-D-galactopyranosyl-
(1→4)-3-O-benzyl-2-O-chloroacetyl-1-thio-α-L-rhamnopyranoside 17
Prepared from S1 according to the General Procedure VI. Colorless oil, 80%, Rf 0.49
(toluene/EtOAc 10:1). 1H-NMR (400 MHz, CDCl3) δ 7.42–7.31 (m, 4H), 7.27–7.04 (m, 39H), 7.02
(d, J = 7.4 Hz, 2H), 5.48–5.43 (m, 1H), 5.29 (d, J = 1.4 Hz, 1H), 5.01 (d, J = 11.0 Hz, 1H), 4.92 (d, J = 7.6 Hz,
1H), 4.87 (d, J = 11.6 Hz, 1H), 4.73 (d, J = 13.7 Hz, 1H), 4.72–4.68 (m, 2H), 4.66–4.55 (m, 5H), 4.47 (d,
J = 11.6 Hz, 1H), 4.42 (d, J = 2.4 Hz, 2H), 4.29–4.20 (m, 4H), 4.16–4.07 (m, 2H), 3.85 (d, J = 2.0 Hz, 2H),
3.75 (d, J = 2.9 Hz, 1H), 3.72–3.64 (m, 5H), 3.54 (dd, J = 10.1, 5.9 Hz, 1H), 3.49–3.41 (m, 1H), 3.42–3.30
(m, 5H), 1.25 (d, J = 6.2 Hz, 3H); 13C-NMR (101 MHz, CDCl3) δ 166.6, 139.0, 138.9, 138.8, 138.6, 138.4,
138.3, 137.8, 137.6, 137.3, 133.3, 131.8, 129.0, 128.9, 128.6, 128.3, 128.2, 128.1, 128.1, 128.0, 128.0, 128.0,
128.0, 127.8, 127.8, 127.7, 127.6, 127.3, 127.2, 125.1, 102.6, 102.2, 85.6, 82.1, 81.7, 80.3, 79.6, 78.4, 75.9, 75.5,




Prepared from 17 and 3 by following general procedure VII. Colorless oil, 42%. Rf 0.14
(toluene/EtOAc 10:1). 1H-NMR (400 MHz, CDCl3) δ 7.37 (d, J = 6.6 Hz, 2H), 7.32–7.08 (m, 48H),
5.80–5.67 (m, 1H), 5.42 (dd, J = 3.0, 2.1 Hz, 1H), 5.11 (d, J = 1.6 Hz, 1H), 5.02 (d, J = 11.0 Hz, 1H), 4.94
(dd, J = 17.2, 1.7 Hz, 1H), 4.94–4.84 (m, 4H), 4.76–4.67 (m, 10H), 4.67–4.45 (m, 4H), 4.43 (d, J = 2.9 Hz,
2H), 4.35–4.24 (m, 5H), 4.19 (d, J = 2.2 Hz, 1H), 4.12 (dd, J = 11.1, 6.5 Hz, 1H), 4.04 (d, J = 9.6 Hz, 1H),
3.95 (d, J = 2.2 Hz, 1H), 3.93–3.88 (m, 1H), 3.85–3.58 (m, 8H), 3.58–3.31 (m, 10H), 2.16–2.05 (m, 2H), 1.92
(s, 3H), 1.77–1.68 (m, 2H), 1.21 (d, J = 6.1 Hz, 3H); 13C-NMR (101 MHz, CDCl3) δ 170.4, 166.1, 139.1,
139.0, 138.9, 138.7, 138.6, 138.5, 138.2, 137.9, 137.8, 137.6, 128.9, 128.4, 128.3, 128.3, 128.2, 128.2, 128.1,
128.1, 128.1, 128.0, 128.0, 128.0, 127.9, 127.8, 127.7, 127.6, 127.5, 127.4, 127.4, 127.3, 127.3, 127.2, 114.9,
104.0, 102.7, 102.4, 99.0, 82.1, 81.8, 81.3, 80.3, 79.6, 78.6, 77.8, 75.6, 75.5, 75.0, 74.6, 74.3, 73.4, 73.4, 73.4,
73.1, 73.1, 72.8, 72.4, 72.0, 71.4, 70.4, 69.8, 69.7, 68.7, 68.1, 62.6, 40.8, 30.1, 28.8, 20.7, 17.9.
2,3,5-Tri-O-benzoyl-α-L-arabinofuranosyl-(1→5)-2,3-di-O-benzoyl-L-arabinofuranosyl N-phenyl
trifluoroacetimidate 8
Prepared from the hemiacetal [19] according to the General Procedure II. White amorphous
solid, 87%. The product was verified by NMR spectroscopy as an α/β mixture and was used in the
subsequent glycosylation without further characterization.
Phenyl 2,3,5-tri-O-benzoyl-α-L-arabinofuranosyl-(1→5)-2,3-di-O-benzoyl-α-L-arabinofuranosyl-
(1→4)-3-O-benzyl-2-O-(2-naphthylmethyl)-1-thio-α-L-rhamnopyranoside 21
Prepared from 8 and 6 according to the General Procedure I. White amorphous solid, 84%. Rf
0.40 (toluene/EtOAc 20:1). 1H-NMR (300 MHz, CDCl3) δ 7.95–7.81 (m, 10H), 7.66–7.61 (m, 1H), 7.57
(m, 3H), 7.46–7.06 (m, 24H), 7.02 (d, J = 7.2 Hz, 1H), 6.98–6.90 (m, 3H), 5.82 (s, 1H), 5.55 (bs, 1H), 5.50
(s, 1H), 5.47 (d, J = 4.7 Hz, 1H), 5.40 (bs, 1H), 5.35 (s, 1H), 4.75–4.57 (m, 5H), 4.56–4.36 (m, 4H), 4.15–3.97
(m, 3H), 3.92–3.76 (m, 3H), 1.29 (d, J = 5.8 Hz, 3H); 13C-NMR (75 MHz, CDCl3) δ 166.0, 165.6, 165.4,
165.0, 164.9, 137.5, 135.1, 134.5, 133.3, 133.2, 133.1, 132.9, 132.8, 131.0, 129.7, 129.6, 129.6, 129.5, 129.1,
128.9, 128.8, 128.7, 128.3, 128.2, 128.1, 127.7, 127.7, 127.5, 127.4, 127.1, 126.6, 125.9, 125.8, 125.8, 106.6,
105.9, 85.9, 82.5, 81.8, 81.5, 81.1, 80.2, 77.6, 77.6, 75.9, 75.5, 72.2, 71.8, 68.7, 66.4, 63.5, 18.0.
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Phenyl α-L-arabinofuranosyl-(1→5)-α-L-arabinofuranosyl-(1→4)-3-O-benzyl-2-O-(2-
naphthylmethyl)-1-thio-α-L-rhamnopyranoside S2
Prepared from 21 according to the General Procedure III. White amorphous solid, 87%. Rf 0.37
(CH2Cl2/MeOH 10:1). 1H-NMR (300 MHz, CDCl3) δ 7.72–7.60 (m, 3H), 7.54 (bs, 1H), 7.39–7.30 (m, 4H),
7.26–7.13 (m, 7H), 7.12–7.07 (m, 2H), 5.38 (s, 1H), 5.32 (s, 1H), 4.93 (s, 1H), 4.66 (d, J = 12.4 Hz, 1H),
4.58 (d, J = 12.5 Hz, 1H), 4.36 (bs, 1H), 4.10 – 3.74 (m, 11H), 3.72–3.50 (m, 4H), 1.23 (d, J = 5.9 Hz, 3H);
13C-NMR (101 MHz, CDCl3) δ 137.5, 134.8, 134.1, 133.0, 132.9, 131.4, 128.9, 128.5, 128.3, 128.1, 127.9,
127.8, 127.6, 127.3, 127.0, 126.1, 126.0, 125.9, 109.0, 107.8, 85.6, 85.3, 83.5, 81.6, 80.6, 79.3, 77.9, 76.8, 76.0,
75.8, 72.0, 71.9, 68.8, 66.3, 61.7, 17.9. Copies of NMR spectra in Supplementary Materials.
Phenyl 2,3,5-tri-O-benzyl-α-L-arabinofuranosyl-(1→5)-2,3-di-O-benzyl-α-L-arabinofuranosyl-
(1→4)-3-O-benzyl-2-O-(2-naphthylmethyl)-1-thio-α-L-rhamnopyranoside 5
Prepared from S2 according to the General Procedure IV. White amorphous solid, 78%. Rf 0.32
(toluene/EtOAc 20:1). 1H-NMR (300 MHz, CDCl3) δ 7.72–7.64 (m, 1H), 7.63–7.56 (m, 3H), 7.39–7.34
(m, 3H), 7.31–7.25 (m, 4H), 7.24–7.11 (m, 29H), 7.03–6.95 (m, 2H), 5.55 (s, 1H), 5.45 (bs, 1H), 5.08 (s, 1H),
4.74 (d, J = 12.5 Hz, 1H), 4.63 (d, J = 12.5 Hz, 1H), 4.60 (s, 1H), 4.49–4.40 (m, 8H), 4.37–4.20 (m, 3H),
4.19–4.00 (m, 3H), 3.97 (dd, J = 5.0, 2.1 Hz, 5H), 3.87–3.73 (m, 3H), 3.64–3.45 (m, 3H), 1.30 (d, J = 5.8 Hz,
3H); 13C-NMR (75 MHz, CDCl3) δ 138.0, 137.9, 137.8, 137.5, 137.5, 135.2, 134.5, 133.0, 132.9, 131.2, 128.9,
128.5, 128.3, 128.3, 128.2, 128.2, 128.1, 127.9, 127.8, 127.7, 127.7, 127.6, 127.6, 127.5, 127.5, 127.2, 127.1,
126.9, 126.6, 126.0, 125.9, 125.8, 107.0, 106.3, 88.4, 88.0, 85.8, 83.4, 80.8, 80.6, 80.2, 76.1, 75.5, 73.3, 72.1,
72.0, 71.8, 71.5, 71.1, 69.5, 69.0, 66.0, 65.2, 17.9.
Phenyl α-L-arabinofuranosyl-(1→4)-3-O-benzyl-2-O-(2-naphthylmethyl)-1-thio-α-
L-rhamnopyranoside 22
Acceptor 6 was glycosylated with donor 11 according to the General Procedure I. The product
was taken directly to the Zemplén deacylation according to General Procedure III. White amorphous
solid, 70% over 2 steps. Rf 0.28 (CH2Cl2/MeOH 10:1). 1H-NMR (400 MHz, CDCl3) δ 7.74–7.59 (m,
4H), 7.41–7.34 (m, 3H), 7.28–7.18 (m, 7H), 7.16–7.09 (m, 3H), 5.41 (s, 1H), 5.39 (d, J = 1.3 Hz, 1H), 4.72
(d, J = 12.4 Hz, 1H), 4.62 (d, J = 12.4 Hz, 1H), 4.39 (d, J = 1.3 Hz, 2H), 4.02 (dd, J = 4.8, 2.2 Hz, 1H),
3.97–3.88 (m, 4H), 3.83 (t, J = 9.4 Hz, 1H), 3.70–3.62 (m, 2H), 3.53 (dd, J = 11.8, 2.0 Hz, 1H), 1.26 (dd,
J = 12.7, 6.1 Hz, 3H); 13C-NMR (101 MHz, CDCl3) δ 137.4, 134.9, 134.1, 133.0, 132.9, 131.3, 128.9, 128.5,
128.2, 128.1, 127.9, 127.8, 127.6, 127.3, 126.9, 126.1, 126.0, 125.9, 109.5, 86.6, 85.6, 79.6, 79.3, 77.8, 76.8,
75.7, 72.0, 71.8, 68.6, 61.5, 17.9.
Phenyl 2,3,5-tri-O-benzoyl-α-L-arabinofuranosyl-(1→5)-α-L-arabinofuranosyl-(1→4)-3-O-benzyl-
2-O-(2-naphthylmethyl)-1-thio-α-L-rhamnopyranoside 23
Prepared from 11 and 22 according to the General Procedure I, but at −78 ◦C. White amorphous
solid, 68%. Rf 0.22 (toluene/EtOAc 4:1). 1H-NMR (300 MHz, CDCl3) δ 8.11–8.04 (m, 2H), 7.98–7.85
(m, 4H), 7.74–7.59 (m, 4H), 7.49–7.04 (m, 22H), 5.53 (d, J = 4.9 Hz, 1H), 5.50 (s, 1H), 5.42 (bs, 1H), 5.28
(s, 1H), 4.80–4.73 (m, 1H), 4.73 (s, 1H), 4.65 (d, J = 13.0 Hz, 1H), 4.60 (dd, J = 12.3, 5.1 Hz, 1H), 4.54–4.49
(m, 1H), 4.46 (d, J = 11.8 Hz, 1H), 4.38 (d, J = 11.8 Hz, 1H), 4.21 (d, J = 2.5 Hz, 1H), 4.03–3.91 (m, 6H),
3.87 (t, J = 9.3 Hz, 1H), 3.73 (dd, J = 10.9, 2.9 Hz, 1H), 3.66 (dd, J = 9.2, 3.0 Hz, 1H), 1.27 (d, J = 6.0 Hz,
3H); 13C-NMR (75 MHz, CDCl3) δ 166.1, 165.8, 165.3, 137.5, 135.1, 134.2, 133.5, 133.0, 133.0, 132.9, 131.1,
130.1, 129.8, 129.6, 129.5, 128.9, 128.6, 128.6, 128.4, 128.4, 128.2, 128.2, 128.1, 128.0, 127.8, 127.8, 127.6,
127.2, 126.6, 126.0, 125.9, 109.7, 106.0, 85.7, 85.5, 81.8, 81.8, 79.6, 79.3, 78.1, 77.4, 77.3, 75.5, 72.1, 71.5, 68.5,
67.1, 63.4, 18.1.
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Phenyl 2,3,5-tri-O-benzyl-α-L-arabinofuranosyl-(1→5)-2,3-di-O-benzyl-α-L-arabinofuranosyl-
(1→4)-3-O-benzyl-1-thio-α-L-rhamnopyranoside S3
Prepared from 5 according to the General Procedure V. White amorphous solid, 73%. Rf 0.21
(toluene/EtOAc 10:1). 1H-NMR (300 MHz, CDCl3) δ 7.39–7.34 (m, 2H), 7.26–7.12 (m, 31H), 7.07 (dd,
J = 6.6, 3.0 Hz, 2H), 5.47 (s, 1H), 5.45 (d, J = 1.3 Hz, 1H), 5.06 (s, 1H), 4.59 (d, J = 11.5 Hz, 1H), 4.52 (d,
J = 11.2 Hz, 1H), 4.48–4.24 (m, 10H), 4.20–4.07 (m, 4H), 4.01–3.92 (m, 3H), 3.86–3.73 (m, 4H), 3.62–3.43
(m, 3H), 2.31 (brs, 1H), 1.24 (d, J = 6.2 Hz, 3H); 13C-NMR (75 MHz, CDCl3) δ 138.0, 137.8, 137.8, 137.4,
137.4, 137.2, 134.0, 131.2, 128.9, 128.5, 128.3, 128.2, 128.2, 128.2, 127.9, 127.8, 127.7, 127.6, 127.5, 127.5,
127.4, 106.9, 106.3, 88.3, 88.0, 86.9, 83.4, 83.3, 81.0, 80.6, 80.3, 75.4, 73.2, 72.1, 72.0, 71.8, 71.6, 71.3, 69.5,
69.3, 68.3, 66.1, 17.7. Copies of NMR spectra in Supplementary Materials.
Phenyl 2,3,5-tri-O-benzyl-α-L-arabinofuranosyl-(1→5)-2,3-di-O-benzyl-α-L-arabinofuranosyl-
(1→4)-3-O-benzyl-2-O-chloroacetyl-1-thio-α-L-rhamnopyranoside 24
Prepared from S3 according to the General Procedure VI. White amorphous solid, 94%. Rf 0.52
(toluene/EtOAc 10:1). 1H-NMR (300 MHz, CDCl3) δ 7.41–7.33 (m, 2H), 7.28–7.09 (m, 31H), 7.07–7.01
(m, 2H), 5.59–5.55 (m, 1H), 5.47 (s, 1H), 5.34 (d, J = 1.5 Hz, 1H), 5.07 (s, 1H), 4.62 (d, J = 11.2 Hz, 1H),
4.50–4.38 (m, 7H), 4.38–4.20 (m, 4H), 4.20–4.09 (m, 3H), 3.99 (s, 2H), 3.97–3.93 (m, 3H), 3.88–3.80 (m,
3H), 3.75 (t, J = 10.8 Hz, 1H), 3.64–3.44 (m, 3H), 1.27 (d, J = 6.2 Hz, 3H); 13C-NMR (75 MHz, CDCl3) δ
166.7, 137.9, 137.7, 137.4, 137.3, 137.0, 133.4, 131.8, 129.0, 128.4, 128.3, 128.2, 128.2, 127.7, 127.6, 127.6,
127.5, 127.5, 106.9, 106.2, 88.1, 87.9, 85.7, 83.4, 83.3, 81.1, 80.6, 78.2, 75.4, 73.2, 72.1, 72.0, 71.7, 71.5, 71.3,




Furnished from 24 and 3 with general procedure VII. Colorless oil, 42%. Rf 0.15 (toluene/EtOAc
10:1). 1H-NMR (400 MHz, CDCl3) δ 7.33–7.08 (m, 40H), 5.78 (ddt, J = 16.9, 10.2, 6.6 Hz, 1H),
5.55–5.52 (m, 1H), 5.39 (d, J = 7.2 Hz, 1H), 5.11 (d, J = 1.6 Hz, 1H), 5.07 (s, 1H), 5.02–4.89 (m, 2H),
4.87 (d, J = 11.1 Hz, 1H), 4.78–4.70 (m, 2H), 4.62 (t, J = 10.6 Hz, 1H), 4.50–4.39 (m, 6H), 4.39–4.21 (m, 8H),
4.16–4.04 (m, 4H), 3.98–3.81 (m, 8H), 3.82–3.68 (m, 5H), 3.66–3.41 (m, 5H), 2.17–2.08 (m, 2H), 1.98 (s, 3H),
1.79–1.68 (m, 2H), 1.23 (d, J = 6.1 Hz, 3H). 13C-NMR (75 MHz, CDCl3) δ 170.4, 166.2, 138.1, 137.9, 137.8,
137.8, 137.7, 137.7, 137.4, 137.4, 128.4, 128.3, 128.3, 128.2, 128.1, 127.9, 127.7, 127.7, 127.6, 127.5, 114.9,
106.7, 106.2, 103.9, 99.0, 88.2, 87.9, 83.3, 83.3, 81.0, 80.6, 80.5, 78.5, 77.8, 74.9, 73.5, 73.3, 73.2, 72.1, 72.0,
71.8, 71.6, 71.4, 71.2, 69.9, 69.7, 69.5, 68.3, 65.8, 62.5, 40.7, 30.1, 28.8, 20.7, 17.8.
4. Conclusions
The syntheses of two fully protected tetrasaccharides with diarabinan and digalactan side chains
designed for assembly of larger RG-I oligosaccharides have been performed. The TMSOTf-promoted
coupling of diarabinan and digalactan donors with a rhamnose thioglycoside acceptor gave two
trisaccharide donors. These could be coupled selectively with an n-pentenyl galactoside acceptor.
We envision that the prepared tetrasaccharides could be versatile building blocks for the synthesis of
larger branched fragments of RG-I. We are currently working on the preparation of branched RG-I and
examining if 1 and 2 can serve as glycosyl donors for this purpose.
Supplementary Materials: Copies of NMR spectra for title compounds and S1–S3 can be found in the
Supplementary Materials.
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